Skip to main content

Table 4 Drug-pathway association in the DTPN of basal BC subtype

From: In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition

Drug Pathway NE nNE and PCI (vs NE = 0.3445)
Fluorouracil Aryl hydrocarbon receptor signaling (1); salvage pathways of pyrimidine deoxyribonucleotides (2) 0.3445 (1) 0.3241 (PCI 5.9%)
(2) 0.3425 (PCI 0.56%)
(1–2) 0.3208 (PCI 6.86%)
Capecitabine Triacylglycerol degradation 0.3445 0.3429 (PCI 0.46%)
Fulvestrant Aryl hydrocarbon receptor signaling 0.3445 0.3241 (PCI 5.9%)
Methotrexate Salvage pathways of pyrimidine deoxyribonucleotides 0.3445 0.3425 (PCI 0.56%)
Raloxifene Aryl hydrocarbon receptor signaling 0.3445 0.3241 (PCI 5.9%)
Tamoxifene Aryl hydrocarbon receptor signaling 0.3445 0.3241 (PCI 5.9%)